Stockscreener 앱 받기
1.13
0.88%
-0.01
시장 영업 전:
1.13
전일 마감가:
$1.14
열려 있는:
$1.15
하루 거래량:
348.91K
Relative Volume:
0.23
시가총액:
$34.89M
수익:
$642.00K
순이익/손실:
$-69.90M
주가수익비율:
-0.158
EPS:
-7.152
순현금흐름:
$-57.62M
1주 성능:
-0.88%
1개월 성능:
-1.74%
6개월 성능:
-40.84%
1년 성능:
-17.52%
1일 변동 폭
$1.13
$1.175
1주일 범위
$1.07
$1.19
52주 변동 폭
$1.01
$8.08
바이오엑셀 테라퓨틱스 Stock (BTAI) Company Profile
명칭
Bioxcel Therapeutics Inc
전화
203-643-8060
주소
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.13 | 35.20M | 642.00K | -69.90M | -57.62M | -7.152 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
바이오엑셀 테라퓨틱스 Stock (BTAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Rodman & Renshaw | Buy |
| 2024-02-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2023-07-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-01 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-06 | 재확인 | BofA Securities | Buy |
| 2021-11-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-02-01 | 개시 | UBS | Buy |
| 2020-10-30 | 개시 | Goldman | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-04 | 개시 | Guggenheim | Buy |
| 2020-04-01 | 개시 | BofA/Merrill | Buy |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
모두보기
바이오엑셀 테라퓨틱스 주식(BTAI)의 최신 뉴스
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com - Investing.com Nigeria
BioXcel CFO Richard Steinhart sells $7,426 of stock By Investing.com - Investing.com India
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock By Investing.com - Investing.com Nigeria
BioXcel Therapeutics CEO Mehta sells $21,108 in company stock - Investing.com India
BioXcel CFO Richard Steinhart sells $7,426 of stock - Investing.com UK
BioXcel Therapeutics chief legal officer sells $7,111 in stock - Investing.com
BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock - Investing.com
BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment - Stock Titan
BioXcel Therapeutics (BTAI) executive sells shares after RSU vesting for taxes - Stock Titan
BioXcel (BTAI) CFO exercises 17,500 RSUs and sells 6,845 shares for taxes - Stock Titan
BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations - Stock Titan
BioXcel Shareholder Notice - TMX Newsfile
BTAI Should I Buy - Intellectia AI
BioXcel Therapeutics (BTAI) Form 144: 19,419 RSUs vested, 30.9M shares outstanding - Stock Titan
BioXcel Therapeutics (NASDAQ: BTAI) notice to sell 6,560 vested restricted shares - Stock Titan
BioXcel Therapeutics (BTAI) Rule 144: 6,845 shares from vested RSUs - Stock Titan
[144] BioXcel Therapeutics, Inc. SEC Filing - Stock Titan
Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026? EPS Not - GuruFocus
BioXcel Therapeutics, Inc. (BTAI) reports Q1 loss, lags revenue estimates - MSN
Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026 Results? - GuruFocus
BioXcel Therapeutics (BTAI) Reports First Quarter Revenue and Re - GuruFocus
BioXcel Therapeutics 1Q Loss $12.7M >BTAI - Moomoo
Press Release: BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
BioXcel Therapeutics Reports Q1 2026 Results, FDA Accepts IGALMI sNDA for At-Home Use, and Explores Strategic Options - Minichart
Armistice Capital reports 7.05% stake in BioXcel (NASDAQ: BTAI) - Stock Titan
BioXcel weighs sale, other strategic options as New Haven biotech continues losses - Hartford Business Journal
BTAI Financials: Income Statement, Balance Sheet & Cash Flow | Bioxcel Therapeutics Inc - Stock Titan
BioXcel Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
BioXcel Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - The Manila Times
BioXcel Therapeut reports Q1 2026 net loss $12.7M, revenue $0.2M; FDA sets IGALMI at-home PDUFA Nov 14, 2026 - TradingView
BioXcel Therapeutics 1Q 2026: Revenue $206K, Net income ($12.69M), EPS ($0.54) — 10-Q Summary - TradingView
BioXcel Therapeutics (NASDAQ: BTAI) posts Q1 2026 loss, limited cash and going concern risk - Stock Titan
BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioXcel Therapeutics (BTAI) posts Q1 2026 loss amid going concern risk - Stock Titan
BioXcel at-home agitation drug gets Nov. 14, 2026 FDA action date - Stock Titan
Number of shareholders of BioXcel Therapeutics, Inc. – SWB:BX20 - TradingView
AI For Pharma And Biotech Market Is Going to Boom | BioXcel Therapeutics, BenevolentAI, NVIDIA Corporation - openPR.com
BioXcel Therapeutics, Inc. (BTAI) Latest Stock News & Headlines - Yahoo Finance
BioXcel Therapeutics (BTAI) CEO exercises 18,000 RSUs, updates share holdings - Stock Titan
BioXcel Therapeutics (BTAI) CFO converts 9,000 RSUs, now holds 15,645 shares - Stock Titan
BioXcel (NASDAQ: BTAI) CSO converts 9,000 RSUs to stock - Stock Titan
Javier Rodriguez of BioXcel (NASDAQ: BTAI) converts 9,000 RSUs to shares - Stock Titan
BioXcel Deadline Alert - TMX Newsfile
BioXcel Therapeutics, Inc. (BTAI) expected to beat earnings estimates: Should you buy? - MSN
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
BioXcel Shareholder Action Reminder - TMX Newsfile
바이오엑셀 테라퓨틱스 (BTAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.92%
4.44%
자본화:
|
볼륨(24시간):